A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Trial Profile

A Phase 1, First in Human, Open Label, Dose Escalation Study of AMV564, a CD33 x CD3 Tandem Diabody in Patients With Relapsed or Refractory Acute Myeloid Leukemia

Recruiting
Phase of Trial: Phase I

Latest Information Update: 29 Nov 2017

At a glance

  • Drugs AMV 564 (Primary)
  • Indications Acute myeloid leukaemia
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Amphivena Therapeutics
  • Most Recent Events

    • 04 May 2017 Status changed from planning to recruiting.
    • 12 Aug 2016 New trial record
    • 10 Aug 2016 According to Amphivena Therapeutics media release, company plans to initiate this study this year.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top